Sumatriptan/naproxen sodium combination for the treatment of migraine

References

• Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. 2nd edition. Cephalalgia24(Suppl. 1), 1–154 (2004).
   Web of Science ®Google Scholar
• Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache41(7), 646–657 (2001).
   PubMed Web of Science ®Google Scholar
• Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch. Intern. Med.159(8), 813–818(1999).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache39(Suppl. 2), 20–26 (1999).
   Google Scholar
• Bigal M, Rapoport A, Aurora S, Sheftell F, Tepper S, Dahlof C. Satisfaction with current migraine therapy: experience from 3 US Centers in US and Sweden. Headache47(4), 475–479 (2007).
   PubMed Web of Science ®Google Scholar
• Kori SH, Sandefer EP, McDonald SA et al. Improved disintegration and gastric emptying of sumatriptan tablets formulated with RT Technology. Presented at: 57th American Academy of Neurology Annual Meeting. FL, USA, 9–16 April, 2005 (Abstract P06.031).
   Google Scholar
• Kori SH, McDonald SA, Page RC et al. Gastric transit and absorption of reformulated and conventional sumatriptan tablets in migraineurs both during and outside of a migraine attack: evaluation by gastric scintigraphy. Presented at: 58th American Academy of Neurology Annual Meeting. CA, USA, 1–6 April 2006 (Abstract P06.184).
   Google Scholar
• Walls C, Lewis A, Bullman J et al. Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. Curr. Med. Res. Opin.20(6), 803–809 (2004).
   PubMed Web of Science ®Google Scholar
• Kori S, Byrd SC, Doll WJ et al. Gastric transit and absorption of sumatriptan and naproxen form a fixed single-tablet sumatriptan RT technology 85 mg and naproxen sodium 500 mg in migraineurs both during and outside a migraine attack: evaluation by gastric scintigraphy. Presented at: 49th Annual Scientific Meeting American Headache Society. IL, USA, 7–11 June 2007 (Abstract F02).
   Google Scholar
• Coulie B, Tack J, Maes B, Geypens B, De Roo M, Janssens J. Sumatriptan, a selective 5-HT1 receptor agonist, induces a lag phase for gastric emptying of liquids in humans. Am. J. Physiol.272(4 Pt 1), G902–G908 (1997).
   PubMed Web of Science ®Google Scholar
• Houghton LA, Fowler P, Keene ON, Read NW. Effect of sumatriptan, a new selective 5HT1-like agonist, on liquid gastric emptying in man. Aliment. Pharmacol. Ther.6(6), 685–691 (1992).
   PubMedGoogle Scholar
• GlaxoSmithKline Sumatriptan Periodic safety Update Report, 01 April 2005 to September 30th 2005. Document number GM/2005/00431/00.
   Google Scholar
• Oral Sumatriptan Dose-Defining Study Group. Sumatriptan: an oral dose-defining study. Eur. Neurol.31(5), 300–305 (1991).
   PubMed Web of Science ®Google Scholar
• Cottrell CK, Gibson JG, Waller SW, Holroyd KA, O’Donnell FJ. The timing of triptan use and its effect on migraine-related disability. Presented at: 10th Congress of the International Headache Society and the American Association for the Study of Headache Scientific Meeting, NY, USA, June 2001 (Abstract P1-F8).
   Google Scholar
• Volans GN. Migraine and drug absorption. Clin. Pharmacokine3(4), 313–318(1978).
   Google Scholar
• Tokola RA. The effect of metoclopramide and prochlorperazine on the absorption of effervescent paracetamol in migraine. Cephalalgia8(3), 139–147 (1988).
   PubMed Web of Science ®Google Scholar
• Tokola RA, Kangasniemi P, Neuvonen PJ, Tokola O. Tolfenamic acid, metoclopramide, caffeine and their combinations in the treatment of migraine attacks. Cephalalgia4(4), 253–263 (1984).
   PubMed Web of Science ®Google Scholar
• Boyle R, Behan PO, Sutton JA. A correlation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method. Br. J. Clin. Pharmacol.30(3), 405–409 (1980).
   Google Scholar
• Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack. Clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain123(8), 1703–1709 (2000).
   PubMed Web of Science ®Google Scholar
• Ferrari MD, James MH, Bates D et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia14(5), 330–338 (1994).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Pascual J, Goadsby PJ et al. Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis. Headache41(8), 754–763 (2001).
   PubMed Web of Science ®Google Scholar
• Krymchantowski AV. Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq. Neuropsichiatr.58(2-B), 428–430 (2000).
   PubMed Web of Science ®Google Scholar
• Smith TR, Sunshine A, Stark SR, Littlefield DE, Spruill SE, Alexander WJ. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache45(8), 983–991 (2005).
   PubMed Web of Science ®Google Scholar
• Krymchantowski AV, Adriano M, Fernandes D. Tolfenamic acid decreased migraine recurrence when used with sumatriptan. Cephalalgia19(3), 186–187 (1999).
   PubMed Web of Science ®Google Scholar
• Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia22(4), 309–312 (2002).
   PubMed Web of Science ®Google Scholar
• Krymchantowski VS, Bigal ME. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the treatment of migraine. BMC Neurol.4, 10 (2004).
   PubMed Web of Science ®Google Scholar
• Brandes JL, Kudrow D, Stark SR et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA297(13), 1443–1454 (2007).
   PubMed Web of Science ®Google Scholar
• Sheftell F, Winner P, Finkel A, Lener S, White J, Nelsen A. Consistent sustained efficacy across 4 migraine attacks with a fixed single-tablet formulation of sumatriptan 85 mg RT technology (and naproxen sodium 500 mg (SumaRT/Nap). Presented at: 49th Annual Scientific Meeting American Headache Society. IL, USA, 6–11 June 2007 (Abstract No F44).
   Google Scholar
• Winner P, Aurora S, Matthew N, Kori S, Lener S, Nelsen A. Migraine free rates across four attacks treated with a fixed single-tablet formulation of sumatriptan 85 mg RT technology (and naproxen sodium 500 mg vs. placebo. Presented at: 49th Annual Scientific Meeting American Headache Society. IL, USA, 6–11 June 2007 (Abstract No S73).
   Google Scholar
• Smith T, Blumenthal H, Diamond M et al. Sumatriptan/naproxen sodium for migraine: efficacy, health related quality of life, and satisfaction outcomes. Headache47(5), 683–692 (2007).
   PubMedGoogle Scholar
• Lipton R, Adelman J, Aurora S, Lener M, White A, Nelsen A. Within person consistency across 4 migraine attacks of a fixed single tablet formulation of sumatriptan 85 mg RT technology (and naproxen sodium 500 mg (sumaRT/nap). Presented at: 59th American Academy of Neurology Annual Meeting. MA, USA, 28 April–5 May 2007 (Abstract No S25.001).
   Google Scholar
• Diamond M, Martin V, Ballard J et al. Patient satisfaction following treatment of a menstrually related migraine and dysmenorrhea with a single-tablet formulation of sumatriptan RT technology and naproxen sodium. Presented at: 49th Annual Scientific Meeting American Headache Society. IL, USA, 6–11 June 2007 (Abstract No S09).
   Google Scholar
• Cady R, Mannix L, Diamond M et al. Work productivity and disability in menstrually related migraines and dysmenorrhea following treatment with a single-tablet formulation of sumatriptan RT technology (and naproxen sodium. Presented at: 49th Annual Scientific Meeting American Headache Society. IL, USA, 6–11 June 2007 (Abstract No S13).
   Google Scholar
• Silberstein S, Goldstein J, Mannix LK et al. Multimechanistic (sumatriptan–naproxen) early intervention for the acute treatment of migraine. Neurology71(2), 114–121 (2008).
   PubMed Web of Science ®Google Scholar
• Winner P, Cady RK, Rouff GE et al. Twelve-month tolerability and safety of sumatriptan-naproxen sodium for the treatment of acute migraine. Mayo Clin. Proc.82(1), 61–68 (2007).
   PubMedGoogle Scholar
• Tansey MJ, Pilgrim AJ, Martin PM. Long-term experience with sumatriptan in the treatment of migraine. Eur. Neurol.33(4), 310–315 (1993).
   PubMedGoogle Scholar
• Dodick D, Lipton RB, Martin V et al. Triptan cardiovascular safety expert panel. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache44(50), 414–425 (2004).
   PubMed Web of Science ®Google Scholar
• Sheftell F, O’Quinn S, Watson C, Pait D, Winter P. Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence. Headache40(2), 103–110 (2000).
   PubMed Web of Science ®Google Scholar
• Sarchielli P, Alberti A, Codini M, Floridi A, Gallai V. Nitric oxide metabolites, prostagl andins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia20(10), 907–918 (2000).
   PubMed Web of Science ®Google Scholar
• Katsarava Z, Schneeweiss S, Kurth T et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology62(5), 788–790 (2004).
   PubMed Web of Science ®Google Scholar